Recent Updates
Recently added Catalysts
RYTM Positive Sentiment

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rhythm Pharmaceuticals has announced that its drug IMCIVREE® (setmelanotide) has received expanded marketing authorization from the MHRA in the United Kingdom. This authorization is specifically for the treatment of obesity and control of hunger in patients aged 4 years and older who suffer from acquired hypothalamic obesity due to hypothalamic injury or impairment. This marks a significant advancement in addressing this rare condition.

Market Sentiment Analysis

POSITIVE FACTORS

  • IMCIVREE® receives expanded marketing authorization in the UK.
  • Authorization applies to patients aged 4 and above.
  • Addresses a specific medical need for hypothalamic obesity.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
3.9%
average across 14 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
RM-131
Phase 1 · Chronic Constipation

Full Press Release Details

-- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on

Frequently Asked Questions

What is IMCIVREE® used for?

IMCIVREE® is used for treating obesity and controlling hunger in patients with acquired hypothalamic obesity.

Who can receive IMCIVREE® in the UK?

Patients aged 4 years and above with acquired hypothalamic obesity due to injury or impairment can receive IMCIVREE®.

Which organization granted the authorization?

The authorization was granted by the MHRA (Medicines and Healthcare products Regulatory Agency).

ShareAdd on Google
Tags: RYTM Viatris Investor Conferences Healthcare Rhythm Pharmaceuticals IMCIVREE setmelanotide hypothalamic obesity UK authorization
Last updated: Aug 11, 2026

Biotech snapshot

Cash runway
$331M liquidity · $16M/mo burn
~20 mo
Low dilution risk
Lead asset
RM-131Phase 1
Chronic Constipation →

Catalyst track record

+53%
best trade around RYTM's most recent catalyst

Peak hindsight return over a 120-day window, across 14 tracked FDA/PDUFA catalysts for RYTM.

See every catalyst's timing & PoA →